Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
3.075
-0.055 (-1.76%)
At close: Aug 28, 2026, 4:00 PM EDT
3.150
+0.075 (2.43%)
After-hours: Aug 28, 2026, 7:42 PM EDT
Quantum BioPharma Employees
Quantum BioPharma had 17 employees as of December 31, 2022. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
n/a
Profits / Employee
-$1,479,927
Market Cap
25.44M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2022 | 17 | 7 | 70.00% | 17 | 0 |
| Dec 31, 2021 | 10 | 1 | 11.11% | 10 | 0 |
| Dec 31, 2020 | 9 | -9 | -50.00% | 9 | 0 |
| Dec 31, 2019 | 18 | -1 | -5.26% | 17 | 1 |
| Sep 30, 2019 | 23 | 4 | 21.05% | 23 | 0 |
| Jun 30, 2019 | 19 | - | - | 19 | 0 |
| Dec 31, 2018 | 19 | - | - | 19 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Evaxion | 46 |
| BeyondSpring | 44 |
| Enlivex | 34 |
| Cerenome | 28 |
| Jasper Therapeutics | 22 |
| Atossa Therapeutics | 16 |
| Tvardi Therapeutics | 12 |
| Cellectar Biosciences | 11 |
QNTM News
- 8 days ago - Quantum Biopharma Provides Corporate Update - GlobeNewsWire
- 15 days ago - Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial - GlobeNewsWire
- 19 days ago - Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: - GlobeNewsWire
- 4 weeks ago - Quantum BioPharma Announces Closing of Debt Settlement - GlobeNewsWire
- 5 weeks ago - Quantum BioPharma Announces Intention to Settle Debt - GlobeNewsWire
- 7 weeks ago - Quantum BioPharma Provides Corporate Update - GlobeNewsWire
- 2 months ago - NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis - GlobeNewsWire
- 2 months ago - Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy - GlobeNewsWire